Evoke measures the spinal cord's electrical response and adjusts stimulation on each pulse. First closed-loop SCS with real-time feedback.
FDA approved 2022; EVA approved Dec 2024; CAP24 approved June 2026.
Updated 30 Jun 2026Checked 10 Oct0 updates this week
Electrodes positioned on the dorsal columns deliver stimulation and sense the electrical response.
System measures evoked compound action potentials—electrical firing of sensory neurons in response.
Algorithm adjusts stimulation to keep the ECAP in the therapeutic window, without patient action.
Evoke uses percutaneous leads or the new CAP24 surgical paddle leads for different anatomies.
| Spec | Evoke Closed-Loop SCS |
|---|---|
| ECAP measurement | On every stimulation pulseR (reported) |
| Adjustment rate | Real-time on every pulseR (reported) |
| Peer-reviewed publications | 37+R (reported) |
| EVA commercial patient visits | 3,000+ (limited release)R (reported) |
R reported by the company
Saluda Medical
Closed-loop SCS, Evoke, neuromodulation
Saluda Medical develops closed-loop spinal cord stimulation that measures and adjusts therapy on each pulse. Evoke got FDA approval; CAP24 paddle lead approved June 2026.
saludamedical.com (opens saludamedical.com)Company profile →
